Taurine flunks the cognition test in pooled trials

Taurine has a reputation as a neuroprotective compound, which has helped fuel its popularity in supplements, yet whether that reputation translates into measurably better thinking has remained controversial. Individual trials have been small and have tested taurine in very different ways: on its own, alongside exercise training, or combined with therapeutic drugs. This meta-analysis set out to pool the randomised evidence and answer a straightforward question: does taurine supplementation actually improve cognitive function, either in people with cognitive impairment or in those without it?

The researchers searched electronic databases up to January 2025 for randomised controlled trials meeting their eligibility criteria. Seven trials qualified, contributing 9 intervention trials and 402 individuals in total, spanning both cognitively impaired and non-impaired populations. The analysis examined taurine administered alone, taurine combined with exercise training, and taurine combined with therapeutic drugs, comparing each against the relevant control condition on cognitive scores. Subgroup analyses probed whether particular combinations or tests told a different story from the overall result.

The headline result was null: taurine, whether given alone or paired with exercise training, produced no significant effect on cognitive scores. Combining taurine with therapeutic drugs was also no better than the drugs alone overall. The one exception emerged in subgroup analysis, where the taurine and drug combination was linked with a significant improvement on the Mini-Mental State Examination, a widely used screening test, with a weighted mean difference of 3.09 points. The authors concluded that the evidence is insufficient to support taurine for enhancing cognitive function.

This result puts distance between taurine's neuroprotective reputation and its measurable effect on cognition in humans, a gap that is common when laboratory promise meets pooled trial data. The evidence base is small, with only 7 trials and 402 people spread across quite different populations and combinations, so the null is not the final word. The isolated Mini-Mental State Examination signal is the sort of finding that needs a dedicated trial to confirm or dismiss. Until larger, better-targeted studies arrive, the question remains open but leaning negative.

This is a reason for scepticism about taking taurine in the hope of sharper thinking: across the pooled trials it moved cognitive scores no more than control conditions did. The single positive subgroup involved people also taking therapeutic drugs, which is a narrow and unconfirmed context rather than a general endorsement. For a general reader, the honest summary is that taurine's cognitive benefits remain unproven on current randomised evidence.